AMIRALIS LTD

Company number 13820102 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

AMIRALIS LTD - Analysis Report

Company Number: 13820102

Analysis Date: 2025-07-20 18:17 UTC

Financial Health Assessment for AMIRALIS LTD


1. Financial Health Score: D

Explanation:
AMIRALIS LTD is currently showing clear symptoms of financial distress, with net current liabilities worsening significantly over the reported periods. The negative shareholders' funds and working capital indicate a lack of sufficient short-term resources to cover immediate obligations. While the company remains active, these financial "vital signs" suggest it is in an unhealthy state, requiring close attention and corrective action.


2. Key Vital Signs

Metric Latest (31 Mar 2024) Interpretation
Current Assets £2,677 Very low level of liquid and short-term assets — "weak pulse" for operations.
Current Liabilities £14,629 Substantially higher than current assets — indicates high short-term debt or payables.
Net Current Assets -£11,952 Negative working capital — "poor circulation" of cash. Company may struggle to meet short-term debts.
Shareholders' Funds -£11,952 Negative equity — indicates accumulated losses exceeding capital invested, "ailing heart" of financial structure.
Trend (2021-2024) Worsening Net current liabilities and negative equity have increased steadily over time, showing progressive financial weakening.

3. Diagnosis

AMIRALIS LTD is experiencing significant financial strain characterized by negative working capital and shareholders' deficit. The company’s "vital signs" reveal that it currently lacks sufficient liquid assets to cover its immediate liabilities, which could threaten its ability to continue as a going concern without additional funding or restructuring.

The consistent increase in liabilities compared to assets points to "symptoms of distress," such as possible cash flow problems and overreliance on creditors or loans. The micro-entity status limits detailed financial disclosures, but the available data clearly shows that the company’s financial "health" is compromised.

However, the company is still operational with a sole director who is also the primary shareholder, meaning decisions can be agile but also dependent on her ability to sustain the business financially and strategically.


4. Recommendations

Immediate Actions:

  • Cash Flow Management: Prioritize improving liquidity by accelerating receivables, delaying non-essential payments, or negotiating extended terms with creditors to ease the "cash flow heartbeat."
  • Capital Injection: Consider additional equity funding or shareholder loans to restore positive net assets and strengthen the balance sheet "immune system."
  • Cost Control: Review and reduce expenses to limit cash burn and improve profitability margins.
  • Financial Planning: Develop a detailed cash flow forecast and budget to monitor financial health closely and anticipate potential shortfalls.

Medium to Long-Term Actions:

  • Business Model Review: Assess the viability of the current artistic creation business model and explore diversification or new revenue streams to boost income.
  • Seek Professional Advice: Engage with financial advisors or turnaround specialists to explore restructuring or refinancing options.
  • Maintain Compliance: Ensure timely filing of accounts and confirmation statements to avoid penalties and preserve credibility with stakeholders.

Perspective: Financial Health Diagnostician · Model: gpt-4.1-mini · Generated 20 July 2025

Sign in to generate a free AI analysis of this company — no password needed, just an email link.